(Q33373813)

26 July 2017

title

Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C. (English)

1 reference

26 July 2017

1 reference

1 reference

T Umemura

1

1 reference

26 July 2017

H Muto

2

1 reference

26 July 2017

E Tanaka

3

1 reference

26 July 2017

A Matsumoto

4

1 reference

26 July 2017

T Ichijo

5

1 reference

26 July 2017

K Yoshizawa

6

1 reference

26 July 2017

T Akamatsu

7

1 reference

26 July 2017

K Kiyosawa

8

1 reference

26 July 2017

Nagano Interferon Treatment Research Group

9

1 reference

26 July 2017

publication date

1 January 2007

1 reference

Journal of Viral Hepatitis

26 July 2017

published in

1 reference

26 July 2017

volume

14

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

48-54

1 reference

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Hepatocellular carcinoma: recent trends in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Seroepidemiology of Helicobacter pylori and Hepatitis A Virus and the Mode of Transmission of Infection: A 9-Year Cohort Study in Rural Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Evaluation of the effects of strain-specific antigen variation on the accuracy of serologic diagnosis of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Clinical and virological profiles in patients with multiple hepatitis virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Effect of hepatitis G virus infection on chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

SEN virus infection and its relationship to transfusion-associated hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Association between SEN virus infection and hepatitis C in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Investigation of SEN Virus Infection in Patients with Cryptogenic Acute Liver Failure, Hepatitis‐Associated Aplastic Anemia, or Acute and Chronic Non–A–E Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Mucosal immunity and primary biliary cirrhosis: presence of antimitochondrial antibodies in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Optimal therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Helicobacter pylori infection and immune thrombocytopenic purpura: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00770.X

10.1111/J.1365-2893.2006.00770.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference